CRIXIVAN Drug Patent Profile
✉ Email this page to a colleague
When do Crixivan patents expire, and what generic alternatives are available?
Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA.
The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Additional details are available on the indinavir sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CRIXIVAN?
- What are the global sales for CRIXIVAN?
- What is Average Wholesale Price for CRIXIVAN?
Summary for CRIXIVAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Clinical Trials: | 11 |
| Patent Applications: | 5,101 |
| Drug Prices: | Drug price information for CRIXIVAN |
| What excipients (inactive ingredients) are in CRIXIVAN? | CRIXIVAN excipients list |
| DailyMed Link: | CRIXIVAN at DailyMed |
Recent Clinical Trials for CRIXIVAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oncology Institute of Southern Switzerland | Phase 2 |
| Emory University | Phase 4 |
| National Institutes of Health Clinical Center (CC) | Phase 1 |
US Patents and Regulatory Information for CRIXIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-006 | Apr 19, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-001 | Mar 13, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-003 | Mar 13, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-005 | Dec 17, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CRIXIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-005 | Dec 17, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-006 | Apr 19, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-003 | Mar 13, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Merck Sharp Dohme | CRIXIVAN | indinavir sulfate | CAPSULE;ORAL | 020685-001 | Mar 13, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CRIXIVAN
See the table below for patents covering CRIXIVAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 116925 | Combinations of compounds useful for treating HIV infections and pharmaceutical compositions comprising these combinations | ⤷ Sign Up |
| Bulgaria | 100016 | ⤷ Sign Up | |
| Spain | 2188604 | ⤷ Sign Up | |
| Romania | 115726 | DERIVATI SUBSTITUITI AI PENTANAMIDEI, PROCEDEU DE OBTINERE, INTERMEDIARI IN SINTEZA ACESTORA, COMPOZITIE CARE II CONTINE, SI METODE DE TRATAMENT (SUBSTITUTED DERIVATIVES OF PENTANEAMIDE, PROCESS FOR THEIR PREPARATION, INTERMEDIATES USED IN THEIR SYNTHESIS, COMPOSITION CONTAINING THE SAME AND METHODS OF TREATMENT) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
